This study also reveals a new TRAIL resistance mechanism that provides a new theoretical basis for the co-therapy of the EGFR monoclonal antibody cetuximab, PD-L1 inhibitors, and human recombinant TRAIL in GCa cases. This evidence concerns the gene CD274 and temporal arteritis.